MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline
22.7.2021 16:00:00 EEST | Business Wire | Press release
MapleStory , the iconic free-to-play global MMORPG from Nexon, has launched Neo: Light’s Wrath, Part Two of the massive summer content update that offers all new desert area, Hotel Arcus, offering new quests available to players level 270 and above. The Neo: Light’s Wrath update also adds the new Boss Seren and continues the Neo Castle, Tera Burning and Burning World Events.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005292/en/
MapleStory’s Neo: Light's Wrath Update Unveils New Boss Seren and Hotel Arcus Questline (Photo: Business Wire)
Hidden secrets of the ancient gods will be unveiled in the Hotel Arcus desert area which has opened for players who have reached Level 270 and have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest. Following clues from the ancient gods will reveal the mysteries of the Hotel Arcus, offering a series of quests that will reward players with the Sacred Symbol: Arcus upon completion. After all Hotel Arcus quests are completed players can perform daily quests for Archelon in the Hotel Arcus Saloon that will reward Sacred Symbol: Arcus.
With the battle at Cernium at its end, Seren has emerged as god incarnate, wielding the power of the ancient gods. Players level 265 who have completed the 5th job advancement along with the “[Cernium (After)] Defensive Tactics” quest are able to test their strength against the powerful new boss Seren by entering a special portal in the Cernium Royal Palace Main Hall. By defeating Seren, players have the chance to earn Mitra’s Nodestone and Mitra’s Rage Emblem, part of the Pitched Boss Set. Mitra’s Nodestone unlocks the Solar Crest skill when used and Mitra’s Rage Emblem provides +40 primary stat/secondary stat for your class and +5 Attack/Magic Attack. Mitra’s Rage is tradable until equipped and can be equipped at level 200.
The Neo: Light’s Wrath Update continues the Neo Castle and Tera Burning and Burning World Events:
Neo Castle Event: Neo Castle is an area shrouded in mystery and was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events and mini-games including new ways to earn NEO currency with the following features and shops available:
- Neo Stone Shop: Players can exchange Neo Stones for a variety of items that can be used to enhance equipment and boost character growth
- Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop: Neo Cores can be collected by defeating bosses and can be used to purchase a variety of enhancement items
- Neo Meso Shop: The Meso shop is stocked full of useful items and cosmetic items that can be purchased using Mesos
Burning World and Tera Burning Plus: Burning World and Tera Burning Plus events continue to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon if your Tera Burning Plus character reaches Lv. 220. Burning World Leap will begin August 25 and characters Lv. 150 and above will be able to leap to any non-Reboot world in their region.
To learn more about MapleStory , please visit http://maplestory.nexon.net
Assets - Neo: Light’s Wrath Video - Artwork
Social Media: TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005292/en/
Contact information
Brian Klotz
Nexon America
pr@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 15:00:00 EEST | Press release
Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and training workloads, all deployed in data centers throughout the Kingdom. “The future of artificial intelligence depends on the ability to combine world-class inf
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions, expands our addressable market — more than doubling our revenue opportunity per gigawatt of delivered capacity — and allows us to scale both our offerings and the globa
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom